HIV-1 evolution in patients undergoing immunotherapy with Tat, Rev, and Nef expressing dendritic cells followed by treatment interruption-Reference-Cited by-同舟云学术

HIV-1 evolution in patients undergoing immunotherapy with Tat, Rev, and Nef expressing dendritic cells followed by treatment interruption

Published:2013-11-13 Issue:17 Volume:27 Page:2679-2689
ISSN:0269-9370
Container-title:AIDS
language:en
Short-container-title:

Author:

de Goede Anna L.,van Deutekom Hanneke W.M.,Vrancken Bram,Schutten Martin,Allard Sabine D.,van Baalen Carel A.,Osterhaus Albert D.M.E.,Thielemans Kris,Aerts Joeri L.,Keşmir Can,Lemey Philippe,Gruters Rob A.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Infectious Diseases,Immunology,Immunology and Allergy

Reference39 articles.

1. Virus-specific CD8 cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection.;Borrow;J Virol,1994

2. Virus escape from CTL recognition.;Koup;J Exp Med,1994

3. Low frequency of amino acid alterations following therapeutic immunization with HIV-1 Gag p24-like peptides.;Kran;AIDS,2010

4. Phenotypic and functional characteristics of HIV-specific CD8 T cells and gag sequence variability after autologous dendritic cells based therapeutic vaccine.;Lopez;Vaccine,2009

5. Therapeutic vaccination of HIV-1-infected patients on HAART with a recombinant HIV-1 nef-expressing MVA: safety, immunogenicity and influence on viral load during treatment interruption.;Harrer;Antivir Ther,2005

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Fitness Cost of Antiretroviral Drug Resistance Mutations on the pol Gene during Analytical Antiretroviral Treatment Interruption among Individuals Experiencing Virological Failure;Pathogens;2021-11-03

2. Comparative Circulation Dynamics of the Five Main HIV Types in China;Journal of Virology;2020-11-09

3. Antiretroviral Therapy Interruption (ATI) in HIV-1 Infected Patients Participating in Therapeutic Vaccine Trials: Surrogate Markers of Virological Response;Vaccines;2020-08-05

4. iHIVARNA phase IIa, a randomized, placebo-controlled, double-blinded trial to evaluate the safety and immunogenicity of iHIVARNA-01 in chronically HIV-infected patients under stable combined antiretroviral therapy;Trials;2019-06-17

5. Dendritic cell immunotherapy followed by cART interruption during HIV-1 infection induces plasma protein markers of cellular immunity and neutrophil recruitment;PLOS ONE;2018-02-01